Literature DB >> 34988594

Specific Characteristic of Hyperplastic Callus in a Larger Cohort of Osteogenesis Imperfecta Type V.

Wen-Bin Zheng1, Jing Hu1, Jia Zhang2, Zheng Yang3, Ou Wang1, Yan Jiang1, Wei-Bo Xia1, Xiao-Ping Xing1, Wei Yu4, Mei Li5.   

Abstract

Hyperplastic callus (HPC) is the most conspicuous features of osteogenesis imperfecta (OI) type V, of which accurate diagnosis and treatment are facing challenges. We investigate the clinical features, and impact factors of HPC in OI type V patients. In this retrospective single-center study, a total of 21 patients with type V OI confirmed by IFITM5 mutation were included. Radiological characteristics of bone were evaluated by X-rays, dual-energy X-ray absorptiometry, and computed tomography scan. Bone biopsy specimens were performed and stained by routine hematoxylin-eosin. The effects of bisphosphonates on HPC were investigated. Eleven patients (52.3%) had HPCs at 19 skeletal sites, 11 of which affected the femur. Three patients developed four (21.1%) HPCs after fractures, and 15 (78.9%) HPCs occurred in absence of bone fracture. The progress of HPCs was variable, of which most HPCs enlarged in the initial phase and remained stable, and only one HPC dwindled in size. One patient had a rapidly growing mass on the right humerus, and biopsy showed irregular trabeculae of woven bone and immature bone and cartilage in the loose and edematous collagenous network without signs of tumor. Bisphosphonates treatment had no significant effects on HPC of OI patients. HPC is the specific characteristic of OI type V patients, and its location, shape, size, and progression are variable, and the femur is the most frequently involved site. It is very important to make a diagnosis of HPC through detecting IFITM5 mutation and completing pathological diagnosis if necessary. The treatment of HPC is worth further exploration.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hyperplastic callus formation; IFITM5; Osteogenesis imperfecta type V; Osteosarcoma

Mesh:

Substances:

Year:  2022        PMID: 34988594     DOI: 10.1007/s00223-021-00932-2

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  29 in total

1.  MRI and CT features of hyperplastic callus in osteogenesis imperfecta tarda.

Authors:  I Dobrocky; G Seidl; F Grill
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

2.  Hyperplastic callus formation in osteogenesis imperfecta.

Authors:  Janez Lamovec; Eva Mozina; Bostjan Baebler
Journal:  Ann Diagn Pathol       Date:  2003-08       Impact factor: 2.090

Review 3.  Osteogenesis imperfecta: an update on clinical features and therapies.

Authors:  Ronit Marom; Brien M Rabenhorst; Roy Morello
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.664

4.  Type V osteogenesis imperfecta: a new form of brittle bone disease.

Authors:  F H Glorieux; F Rauch; H Plotkin; L Ward; R Travers; P Roughley; L Lalic; D F Glorieux; F Fassier; N J Bishop
Journal:  J Bone Miner Res       Date:  2000-09       Impact factor: 6.741

5.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

6.  A nonclassical IFITM5 mutation located in the coding region causes severe osteogenesis imperfecta with prenatal onset.

Authors:  Heike Hoyer-Kuhn; Oliver Semler; Lutz Garbes; Katharina Zimmermann; Jutta Becker; Bernd Wollnik; Eckhard Schoenau; Christian Netzer
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

7.  Natural history of hyperplastic callus formation in osteogenesis imperfecta type V.

Authors:  Moira S Cheung; Francis H Glorieux; Frank Rauch
Journal:  J Bone Miner Res       Date:  2007-08       Impact factor: 6.741

8.  Osteogenesis imperfecta type V: Genetic and clinical findings in eleven Chinese patients.

Authors:  Yi Liu; Jiawei Wang; Doudou Ma; Fang Lv; Xiaojie Xu; Weibo Xia; Yan Jiang; Ou Wang; Xiaoping Xing; Peiran Zhou; Jianyi Wang; Wei Yu; Mei Li
Journal:  Clin Chim Acta       Date:  2016-09-25       Impact factor: 3.786

9.  A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor.

Authors:  Charles R Farber; Adi Reich; Aileen M Barnes; Patricia Becerra; Frank Rauch; Wayne A Cabral; Alison Bae; Aaron Quinlan; Francis H Glorieux; Thomas L Clemens; Joan C Marini
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

Review 10.  Osteogenesis imperfecta.

Authors:  Joan C Marini; Antonella Forlino; Hans Peter Bächinger; Nick J Bishop; Peter H Byers; Anne De Paepe; Francois Fassier; Nadja Fratzl-Zelman; Kenneth M Kozloff; Deborah Krakow; Kathleen Montpetit; Oliver Semler
Journal:  Nat Rev Dis Primers       Date:  2017-08-18       Impact factor: 52.329

View more
  1 in total

1.  The Osteogenesis Imperfecta Type V Mutant BRIL/IFITM5 Promotes Transcriptional Activation of MEF2, NFATc, and NR4A in Osteoblasts.

Authors:  Vincent Maranda; Marie-Hélène Gaumond; Pierre Moffatt
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.